赛诺医疗公告，股票交易连续30个交易日内日收盘价格涨幅偏离值累计达到200%，属于股票交易严重异常波动情形。经核实，公司目前日常生产经营情况正常，市场环境、行业政策等均未发生重大调整。此外，公司控股子公司赛诺神畅自主研发的COMETIU自膨式颅内药物涂层支架系统及COMEX球囊微导管获得美国FDA突破性医疗器械认定，并不最终保障该产品后续在美国FDA的上市申请一定获得批准。截至8月15日，公司股票收盘价为34.57元/股，近期公司股价累计涨幅较大，超过大部分同行业公司股价涨幅及上证指数涨幅，可能存在短期上涨过快出现的下跌风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.